New Two-Pronged attack tested for tough brain cancers
NCT ID NCT07468136
Summary
This study is testing a combination of two drugs, retifanlimab and DFMO, for people with aggressive brain tumors that have started growing again. The first goal is to find a safe and tolerable dose of DFMO to give with retifanlimab. Researchers will then see if this combination helps the immune system fight the cancer better than retifanlimab alone and if it can slow the tumor's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.